UBS Group’s IO Biotech IOBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-30,980
| Closed | -$1.83K | – | 10722 |
|
|
2026
Q1 | $1.83K | Sell |
30,980
-12,598
| -29% | -$4.3K | ﹤0.01% | 9424 |
|
|
2025
Q4 | $26.5K | Buy |
43,578
+36,565
| +521% | +$27.2K | ﹤0.01% | 7594 |
|
|
2025
Q3 | $2.55K | Sell |
7,013
-6,246
| -47% | -$10.8K | ﹤0.01% | 9154 |
|
|
2025
Q2 | $18.4K | Buy |
13,259
+904
| +7% | +$1.03K | ﹤0.01% | 8498 |
|
|
2025
Q1 | $13.5K | Sell |
12,355
-34,675
| -74% | -$32.7K | ﹤0.01% | 8459 |
|
|
2024
Q4 | $43.3K | Sell |
47,030
-60,876
| -56% | -$60.5K | ﹤0.01% | 7390 |
|
|
2024
Q3 | $113K | Buy |
107,906
+104,626
| +3,190% | +$132K | ﹤0.01% | 6264 |
|
|
2024
Q2 | $3.84K | Buy |
+3,280
| New | +$4.58K | ﹤0.01% | 8167 |
|
|
2024
Q1 | – | Sell |
-11,204
| Closed | -$21.1K | – | 9658 |
|
|
2023
Q4 | $21.1K | Buy |
+11,204
| New | +$13.4K | ﹤0.01% | 7075 |
|
|
2022
Q3 | – | Sell |
-2,234
| Closed | -$10K | – | 10617 |
|
|
2022
Q2 | $10K | Buy |
+2,234
| New | +$13.7K | ﹤0.01% | 7966 |
|
UBS Group's IOBT Position: Q2 2026 in Review
UBS Group sold out of IO Biotech (IOBT) in Q2 2026, closing a stake of 30,980 shares — an estimated $1.83K sold.
UBS Group first reported a position in IOBT in Q2 2022 and held it in 10 quarters. The position peaked at $113K in Q3 2024. 0 funds tracked by Wall St. Rank hold IOBT as of Q2 2026.
- UBS Group reported no remaining IO Biotech position as of Q2 2026 after selling out during the quarter.
- UBS Group sold 30,980 IO Biotech shares in Q2 2026, an estimated $1.83K.
- UBS Group first reported a position in IO Biotech in Q2 2022 and held it in 10 quarters.
- UBS Group's IO Biotech position peaked at $113K in Q3 2024.
- 0 funds tracked by Wall St. Rank held IO Biotech as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.